New Brunswick is reimbursing, through its public health insurance program, the cost of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) for eligible residents living with amyotrophic lateral sclerosis (ALS). The Canadian province is the country’s fourth to provide public coverage for the oral therapy — marketed in the U.S.
New Brunswick adds Albrioza for ALS to its public health plan
Six months of treatment with clenbuterol, an asthma medication, slowed disease progression in adults with amyotrophic lateral sclerosis (ALS), according to data from a small U.S.-based Phase 2 clinical trial. Despite these promising preliminary findings, more than half the participants withdrew from the study due to side effects. “Nonetheless,…
It’s long been known that some molecules are misplaced in the nerve cells that progressively die in amyotrophic lateral sclerosis (ALS), but a new study shows this affects hundreds of different molecules, not just a handful, as previously thought. “This research represents a shift in our thinking about what…
Throughout our relationship, my late husband, Jeff, was the partner who most enjoyed taking care of people and things. He built wooden furniture and personal gifts, tended to flowers, and prepared meals from scratch. He got a great deal of satisfaction from going above and beyond for people. Jeff was…
Did you know that more than 16% of ALS patients have served in the military? Are you aware that veterans are twice as likely to develop ALS as those who haven’t been in the military? If not staggering, those facts are compelling. Many theories have been put…
Athira Pharma’s experimental therapy ATH-1105 shows anti-inflammatory and neuroprotective effects, promoting neuron growth and reducing damage associated with mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a related condition. The small molecule reduced inflammation and the buildup of a faulty version of TDP-43, a protein that’s…
A new home-based neurocognitive platform from Cumulus Neurosciences is feasible to use and patient-friendly, and shows potential to identify cognitive problems and to discriminate between people with amyotrophic lateral sclerosis (ALS), those with frontotemporal dementia (FTD), and healthy individuals. That’s according to preliminary data from a first-in-class study,…
Eighteen years ago when expecting my daughter, I decided to become a stay-at-home mom. Mothering a newborn was a joyful season, but it was also exhausting and isolating. Another new mom in my community who’d experienced that same isolation after leaving the workforce started a family club that offered an…
Dimethyl fumarate (DMF) — an oral medication approved for multiple sclerosis — and H-151, an experimental treatment, can suppress inflammatory and abnormal immune pathways thought to be involved in sporadic amyotrophic lateral sclerosis (ALS). These are the findings of a study using immune cells from sporadic ALS patients…
I’ll admit I often worry if I’m being productive with my time and spending it wisely. That’s always been important to me, but it intensified the day I was told I had ALS. That’s when I heard the words “average life expectancy of two to five years” and left…
Recent Posts
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’